Dogs in the standard - dose and low - dose
pimobendan groups had
significantly longer median survival times than dogs in the conventional group (334, 277 and 136 days, respectively; P < 0.001).
The EPIC study (Evaluation of
Pimobendan In Cardiomegaly) found pimobendan extended the asymptomatic period by an average of 15 months, while dogs that received the drug also lived significantly longer than those receiving
Pimobendan In Cardiomegaly) found
pimobendan extended the asymptomatic period by an average of 15 months, while dogs that received the drug also lived significantly longer than those receiving
pimobendan extended the asymptomatic period by an average of 15 months, while dogs that received the drug also lived
significantly longer than those receiving a placebo.